VISCHER advises Mosanna Therapeutics on its Seed Financing Round

Mosanna Therapeutics, a Basel-based biotechnology company, has closed a Seed Financing Round led by Forty51 Ventures. The proceeds will be used for formulation and manufacturing optimization of the molecule MOS118 and for regulatory activities in preparation of the first Phase 1b clinical trial. Mosanna is developing the advanced small molecule MOS118, formerly know as AVE0118, for the treatment of metabolic obstructive sleep apnea.

VISCHER has advised Mosanna Therapeutics since its incorporation on all Swiss legal matters. The corporate/m&a team includes partner Matthias Staehelin (pictured left) and Timothy Woodtli (associate, pictured right).

VISCHER advises Mosanna Therapeutics on its Seed Financing Round


Launched in 2020 by LC Publishing Group, it is the first digital portal addressed to the Swiss legal market.
In terms of contents, the website focuses on both law firms and in-house legal departments, covering the latest news and rumors on deals and operations (and the related advisors) as well as on lateral hires, moves and new appointments and providing insights, analytical data and opinions on the professions’ main trends and topics (Ai, innovation, etc.).

For further information, please visit the Group’s website

LC Publishing Group S.p.A. – Via Tolstoi 10 – 20146 Milano – Tel. 0236727659 – C.F./P.IVA 07619210961
REA 1971432 Registro delle Imprese di Milano – Cap. Soc. Euro 50.000,00 i.v.

Copyright 2023 © All rights Reserved. Design by Origami Creative Studio


Share on linkedin
Share on twitter
Share on facebook
Share on whatsapp
Share on email
Share on telegram